A new computational model developed by Johns Hopkins researchers identifies biomarkers that help predict immunotherapy responses in patients with metastatic triple-negative breast cancer. By simulating responses in 1,635 virtual patients, the team discovered on-treatment biomarkers and early tumor diameter changes as promising indicators. This noninvasive approach could improve patient selection for therapy and has potential applications in other cancer types.